<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34445300</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Insulin Signal Transduction Perturbations in Insulin Resistance.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">8590</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22168590</ELocationID>
        <Abstract>
          <AbstractText>Type 2 diabetes mellitus is a widespread medical condition, characterized by high blood glucose and inadequate insulin action, which leads to insulin resistance. Insulin resistance in insulin-responsive tissues precedes the onset of pancreatic β-cell dysfunction. Multiple molecular and pathophysiological mechanisms are involved in insulin resistance. Insulin resistance is a consequence of a complex combination of metabolic disorders, lipotoxicity, glucotoxicity, and inflammation. There is ample evidence linking different mechanistic approaches as the cause of insulin resistance, but no central mechanism is yet described as an underlying reason behind this condition. This review combines and interlinks the defects in the insulin signal transduction pathway of the insulin resistance state with special emphasis on the AGE-RAGE-NF-κB axis. Here, we describe important factors that play a crucial role in the pathogenesis of insulin resistance to provide directionality for the events. The interplay of inflammation and oxidative stress that leads to β-cell decline through the IAPP-RAGE induced β-cell toxicity is also addressed. Overall, by generating a comprehensive overview of the plethora of mechanisms involved in insulin resistance, we focus on the establishment of unifying mechanisms to provide new insights for the future interventions of type 2 diabetes mellitus.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Khalid</LastName>
            <ForeName>Mariyam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Pharmacology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, United Arab Emirates.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alkaabi</LastName>
            <ForeName>Juma</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-2477-0408</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, United Arab Emirates.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khan</LastName>
            <ForeName>Moien A B</ForeName>
            <Initials>MAB</Initials>
            <Identifier Source="ORCID">0000-0003-4970-4618</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Family Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, United Arab Emirates.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adem</LastName>
            <ForeName>Abdu</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-9289-5301</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Pharmacology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, United Arab Emirates.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi P.O. Box 127788, United Arab Emirates.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007333" MajorTopicYN="N">Insulin Resistance</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050417" MajorTopicYN="N">Insulin-Secreting Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">hyperglycemia</Keyword>
        <Keyword MajorTopicYN="N">insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">insulin signaling</Keyword>
        <Keyword MajorTopicYN="N">pancreatic beta cells</Keyword>
        <Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34445300</ArticleId>
        <ArticleId IdType="pmc">PMC8395322</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms22168590</ArticleId>
        <ArticleId IdType="pii">ijms22168590</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barnett D.M., Krall L.P.  Joslin’s Diabetes Mellitus. Lippincott Williams &amp; Wilkins; Philadelphia, PA, USA: 2005. The history of diabetes; pp. 1–17.</Citation>
        </Reference>
        <Reference>
          <Citation>Kang S., Tsai L.T.Y., Rosen E.D. Nuclear Mechanisms of Insulin Resistance. Trends Cell Biol. 2016;26:341–351. doi: 10.1016/j.tcb.2016.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2016.01.002</ArticleId>
            <ArticleId IdType="pmc">PMC4844850</ArticleId>
            <ArticleId IdType="pubmed">26822036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen M.C., Shulman G.I. Mechanisms of Insulin Action and Insulin Resistance. Physiol. Rev. 2018;98:2133–2223. doi: 10.1152/physrev.00063.2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00063.2017</ArticleId>
            <ArticleId IdType="pmc">PMC6170977</ArticleId>
            <ArticleId IdType="pubmed">30067154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mlinar B., Marc J., Janež A., Pfeifer M. Molecular Mechanisms of Insulin Resistance and Associated Diseases. Clin. Chim. Acta. 2007;375:20–35. doi: 10.1016/j.cca.2006.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cca.2006.07.005</ArticleId>
            <ArticleId IdType="pubmed">16956601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mezza T., Cinti F., Cefalo C.M.A., Pontecorvi A., Kulkarni R.N., Giaccari A. β-Cell Fate in Human Insulin Resistance and Type 2 Diabetes: A Perspective on Islet Plasticity. Diabetes. 2019;68:1121–1129. doi: 10.2337/db18-0856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db18-0856</ArticleId>
            <ArticleId IdType="pmc">PMC6905483</ArticleId>
            <ArticleId IdType="pubmed">31109941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muoio D.M., Newgard C.B. Molecular and Metabolic Mechanisms of Insulin Resistance and β-Cell Failure in Type 2 Diabetes. Nat. Rev. Mol. Cell Biol. 2008;9:193–205. doi: 10.1038/nrm2327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2327</ArticleId>
            <ArticleId IdType="pubmed">18200017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimoto W.Y. The Importance of Insulin Resistance in the Pathogenesis of Type 2 Diabetes Mellitus. Am. J. Med. 2000;108:9–14. doi: 10.1016/S0002-9343(00)00337-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9343(00)00337-5</ArticleId>
            <ArticleId IdType="pubmed">10764845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlassara H., Striker G.E. AGE Restriction in Diabetes Mellitus: A Paradigm Shift. Nat. Rev. Endocrinol. 2011;7:526. doi: 10.1038/nrendo.2011.74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrendo.2011.74</ArticleId>
            <ArticleId IdType="pmc">PMC3708644</ArticleId>
            <ArticleId IdType="pubmed">21610689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hotamisligil G.S. Inflammation and Metabolic Disorders. Nature. 2006;444:860–867. doi: 10.1038/nature05485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05485</ArticleId>
            <ArticleId IdType="pubmed">17167474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., et al.  Chronic Inflammation in Fat Plays a Crucial Role in the Development of Obesity-Related Insulin Resistance. J. Clin. Investig. 2003;112:1821–1830. doi: 10.1172/JCI200319451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI200319451</ArticleId>
            <ArticleId IdType="pmc">PMC296998</ArticleId>
            <ArticleId IdType="pubmed">14679177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bril F., Cusi K.  Dermatology and Diabetes. Springer; Berlin/Heidelberg, Germany: 2018. Basic concepts in insulin resistance and diabetes treatment; pp. 19–35.</Citation>
        </Reference>
        <Reference>
          <Citation>Khodabandehloo H., Gorgani-Firuzjaee S., Panahi G., Meshkani R. Molecular and Cellular Mechanisms Linking Inflammation to Insulin Resistance and β-Cell Dysfunction. Transl. Res. 2016;167:228–256. doi: 10.1016/j.trsl.2015.08.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2015.08.011</ArticleId>
            <ArticleId IdType="pubmed">26408801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L., Chen R., Wang H., Liang F. Mechanisms Linking Inflammation to Insulin Resistance. Int. J. Endocrinol. 2015;2015:508409. doi: 10.1155/2015/508409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/508409</ArticleId>
            <ArticleId IdType="pmc">PMC4468292</ArticleId>
            <ArticleId IdType="pubmed">26136779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thévenod F.  Diabetes and Cancer. Volume 19. Karger Publishers; Berlin, Germany: 2008. Pathophysiology of diabetes mellitus type 2: Roles of obesity, insulin resistance and β-cell dysfunction; pp. 1–18.</Citation>
        </Reference>
        <Reference>
          <Citation>Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose Expression of Tumor Necrosis Factor-Alpha: Direct Role in Obesity-Linked Insulin Resistance. Science. 1993;259:87–91. doi: 10.1126/science.7678183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.7678183</ArticleId>
            <ArticleId IdType="pubmed">7678183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meex R.C.R., Blaak E.E., van Loon L.J.C. Lipotoxicity Plays a Key Role in the Development of Both Insulin Resistance and Muscle Atrophy in Patients with Type 2 Diabetes. Obes. Rev. 2019;20:1205–1217. doi: 10.1111/obr.12862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/obr.12862</ArticleId>
            <ArticleId IdType="pmc">PMC6852205</ArticleId>
            <ArticleId IdType="pubmed">31240819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carnagarin R., Dharmarajan A.M., Dass C.R. Molecular Aspects of Glucose Homeostasis in Skeletal Muscle–A Focus on the Molecular Mechanisms of Insulin Resistance. Mol. Cell. Endocrinol. 2015;417:52–62. doi: 10.1016/j.mce.2015.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2015.09.004</ArticleId>
            <ArticleId IdType="pubmed">26362689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tangvarasittichai S. Oxidative Stress, Insulin Resistance, Dyslipidemia and Type 2 Diabetes Mellitus. World J. Diabetes. 2015;6:456. doi: 10.4239/wjd.v6.i3.456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4239/wjd.v6.i3.456</ArticleId>
            <ArticleId IdType="pmc">PMC4398902</ArticleId>
            <ArticleId IdType="pubmed">25897356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sesti G., Federici M., Lauro D., Sbraccia P., Lauro R. Molecular Mechanism of Insulin Resistance in Type 2 Diabetes Mellitus: Role of the Insulin Receptor Variant Forms. Diabetes/Metab. Res. Rev. 2001;17:363–373. doi: 10.1002/dmrr.225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.225</ArticleId>
            <ArticleId IdType="pubmed">11747141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Copps K.D., White M.F. Regulation of Insulin Sensitivity by Serine/Threonine Phosphorylation of Insulin Receptor Substrate Proteins IRS1 and IRS2. Diabetologia. 2012;55:2565–2582. doi: 10.1007/s00125-012-2644-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-012-2644-8</ArticleId>
            <ArticleId IdType="pmc">PMC4011499</ArticleId>
            <ArticleId IdType="pubmed">22869320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boucher J., Kleinridders A., Kahn C.R. Insulin Receptor Signaling in Normal and Insulin-Resistant States. Cold Spring Harb. Perspect. Biol. 2014;6:a009191. doi: 10.1101/cshperspect.a009191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a009191</ArticleId>
            <ArticleId IdType="pmc">PMC3941218</ArticleId>
            <ArticleId IdType="pubmed">24384568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schinner S., Scherbaum W.A., Bornstein S.R., Barthel A. Molecular Mechanisms of Insulin Resistance. Diabet. Med. 2005;22:674–682. doi: 10.1111/j.1464-5491.2005.01566.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1464-5491.2005.01566.x</ArticleId>
            <ArticleId IdType="pubmed">15910615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Humphrey S.J., James D.E., Mann M. Protein Phosphorylation: A Major Switch Mechanism for Metabolic Regulation. Trends Endocrinol. Metab. 2015;26:676–687. doi: 10.1016/j.tem.2015.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tem.2015.09.013</ArticleId>
            <ArticleId IdType="pubmed">26498855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rincon M., Muzumdar R., Atzmon G., Barzilai N. The Paradox of the Insulin/IGF-1 Signaling Pathway in Longevity. Mech. Ageing Dev. 2004;125:397–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15272501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matheny R.W., Jr., Geddis A.V., Abdalla M.N., Leandry L.A., Ford M., McClung H.L., Pasiakos S.M. AKT 2 Is the Predominant AKT Isoform Expressed in Human Skeletal Muscle. Physiol. Rep. 2018;6:e13652. doi: 10.14814/phy2.13652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14814/phy2.13652</ArticleId>
            <ArticleId IdType="pmc">PMC5875533</ArticleId>
            <ArticleId IdType="pubmed">29595878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharjee A., Prasad S.K., Pal S., Maji B., Syamal A.K., Mukherjee S. Synergistic Protective Effect of Folic Acid and Vitamin B12 against Nicotine-Induced Oxidative Stress and Apoptosis in Pancreatic Islets of the Rat. Pharm. Biol. 2016;54:433–444. doi: 10.3109/13880209.2015.1043561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/13880209.2015.1043561</ArticleId>
            <ArticleId IdType="pubmed">25973643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frøsig C., Rose A.J., Treebak J.T., Kiens B., Richter E.A., Wojtaszewski J.F.P. Effects of Endurance Exercise Training on Insulin Signaling in Human Skeletal Muscle: Interactions at the Level of Phosphatidylinositol 3-Kinase, Akt, and AS160. Diabetes. 2007;56:2093–2102. doi: 10.2337/db06-1698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db06-1698</ArticleId>
            <ArticleId IdType="pubmed">17513702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White M.F. Insulin Signaling in Health and Disease. Science. 2003;302:1710–1711. doi: 10.1126/science.1092952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1092952</ArticleId>
            <ArticleId IdType="pubmed">14657487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerf M.E. Beta Cell Dysfunction and Insulin Resistance. Front. Endocrinol. 2013;4:37. doi: 10.3389/fendo.2013.00037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2013.00037</ArticleId>
            <ArticleId IdType="pmc">PMC3608918</ArticleId>
            <ArticleId IdType="pubmed">23542897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. β-Cell Deficit and Increased β-Cell Apoptosis in Humans with Type 2 Diabetes. Diabetes. 2003;52:102–110. doi: 10.2337/diabetes.52.1.102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.52.1.102</ArticleId>
            <ArticleId IdType="pubmed">12502499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahn S.E., Prigeon R.L., McCulloch D.K., Boyko E.J., Bergman R.N., Schwartz M.W., Neifing J.L., Ward W.K., Beard J.C., Palmer J.P. Quantification of the Relationship between Insulin Sensitivity and β-Cell Function in Human Subjects: Evidence for a Hyperbolic Function. Diabetes. 1993;42:1663–1672. doi: 10.2337/diab.42.11.1663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diab.42.11.1663</ArticleId>
            <ArticleId IdType="pubmed">8405710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh Y.S., Bae G.D., Baek D.J., Park E.-Y., Jun H.-S. Fatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells during Development of Type 2 Diabetes. Front. Endocrinol. 2018;9:384. doi: 10.3389/fendo.2018.00384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2018.00384</ArticleId>
            <ArticleId IdType="pmc">PMC6054968</ArticleId>
            <ArticleId IdType="pubmed">30061862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergman R.N., Finegood D.T., Kahn S.E. The Evolution of Β-cell Dysfunction and Insulin Resistance in Type 2 Diabetes. Eur. J. Clin. Investig. 2002;32:35–45. doi: 10.1046/j.1365-2362.32.s3.5.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2362.32.s3.5.x</ArticleId>
            <ArticleId IdType="pubmed">12028373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahn S.E. The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2001;86:4047–4058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11549624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., Ogi K., Hosoya M., Tanaka Y., Uejima H. Free Fatty Acids Regulate Insulin Secretion from Pancreatic β Cells through GPR40. Nature. 2003;422:173–176. doi: 10.1038/nature01478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature01478</ArticleId>
            <ArticleId IdType="pubmed">12629551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitanchez-Mokhtari D., Lahlou N., Kieffer F., Magny J.-F., Roger M., Voyer M. Both Relative Insulin Resistance and Defective Islet β-Cell Processing of Proinsulin Are Responsible for Transient Hyperglycemia in Extremely Preterm Infants. Pediatrics. 2004;113:537–541. doi: 10.1542/peds.113.3.537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.113.3.537</ArticleId>
            <ArticleId IdType="pubmed">14993546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abedini A., Cao P., Plesner A., Zhang J., He M., Derk J., Patil S.A., Rosario R., Lonier J., Song F. RAGE Binds Preamyloid IAPP Intermediates and Mediates Pancreatic β Cell Proteotoxicity. J. Clin. Investig. 2018;128:682–698. doi: 10.1172/JCI85210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI85210</ArticleId>
            <ArticleId IdType="pmc">PMC5785261</ArticleId>
            <ArticleId IdType="pubmed">29337308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms Linking Obesity to Insulin Resistance and Type 2 Diabetes. Nature. 2006;444:840–846. doi: 10.1038/nature05482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05482</ArticleId>
            <ArticleId IdType="pubmed">17167471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeRoith D. β-Cell Dysfunction and Insulin Resistance in Type 2 Diabetes: Role of Metabolic and Genetic Abnormalities. Am. J. Med. 2002;113:3–11. doi: 10.1016/S0002-9343(02)01276-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9343(02)01276-7</ArticleId>
            <ArticleId IdType="pubmed">12431757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabiee A., Krüger M., Ardenkjær-Larsen J., Kahn C.R., Emanuelli B. Distinct Signalling Properties of Insulin Receptor Substrate (IRS)-1 and IRS-2 in Mediating Insulin/IGF-1 Action. Cell. Signal. 2018;47:1–15. doi: 10.1016/j.cellsig.2018.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2018.03.003</ArticleId>
            <ArticleId IdType="pmc">PMC5951756</ArticleId>
            <ArticleId IdType="pubmed">29550500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanti J.-F., Jager J. Cellular Mechanisms of Insulin Resistance: Role of Stress-Regulated Serine Kinases and Insulin Receptor Substrates (IRS) Serine Phosphorylation. Curr. Opin. Pharmacol. 2009;9:753–762. doi: 10.1016/j.coph.2009.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coph.2009.07.004</ArticleId>
            <ArticleId IdType="pubmed">19683471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma M., Aggarwal S., Nayar U., Vikram N.K., Misra A., Luthra K. Differential Expression of Insulin Receptor Substrate-1 (IRS-1) in Visceral and Subcutaneous Adipose Depots of Morbidly Obese Subjects Undergoing Bariatric Surgery in a Tertiary Care Center in North India; SNP Analysis and Correlation with Metabolic Profile. Diabetes Metab. Syndr. Clin. Res. Rev. 2021;15:981–986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33975152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarah Eckstein S., Weigert C., Lehmann R. Divergent Roles of IRS (Insulin Receptor Substrate) 1 and 2 in Liver and Skeletal Muscle. Curr. Med. Chem. 2017;24:1827–1852. doi: 10.2174/0929867324666170426142826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/0929867324666170426142826</ArticleId>
            <ArticleId IdType="pubmed">28462703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gual P., Le Marchand-Brustel Y., Tanti J.-F. Positive and Negative Regulation of Insulin Signaling through IRS-1 Phosphorylation. Biochimie. 2005;87:99–109. doi: 10.1016/j.biochi.2004.10.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2004.10.019</ArticleId>
            <ArticleId IdType="pubmed">15733744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suer F.E.O., Mergen H., Bolu E., Ozata M. Molecular Scanning for Mutations in the Insulin Receptor Substrate-1 (IRS-1) Gene in Turkish with Type 2 Diabetes Mellitus. Endocr. J. 2005;52:593–598. doi: 10.1507/endocrj.52.593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1507/endocrj.52.593</ArticleId>
            <ArticleId IdType="pubmed">16284438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vainshtein I., Kovacina K.S., Roth R.A. The Insulin Receptor Substrate (IRS)-1 Pleckstrin Homology Domain Functions in Downstream Signaling. J. Biol. Chem. 2001;276:8073–8078. doi: 10.1074/jbc.M008436200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M008436200</ArticleId>
            <ArticleId IdType="pubmed">11145958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nandipati K.C., Subramanian S., Agrawal D.K. Protein Kinases: Mechanisms and Downstream Targets in Inflammation-Mediated Obesity and Insulin Resistance. Mol. Cell. Biochem. 2017;426:27–45. doi: 10.1007/s11010-016-2878-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11010-016-2878-8</ArticleId>
            <ArticleId IdType="pmc">PMC5291752</ArticleId>
            <ArticleId IdType="pubmed">27868170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zand H., Morshedzadeh N., Naghashian F. Signaling Pathways Linking Inflammation to Insulin Resistance. Diabetes Metab. Syndr. Clin. Res. Rev. 2017;11:S307–S309. doi: 10.1016/j.dsx.2017.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dsx.2017.03.006</ArticleId>
            <ArticleId IdType="pubmed">28365222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Wang C., Li S., Li W., Yuan G., Pan Y., Chen H. Anti-Diabetic Effects of Inonotus Obliquus Polysaccharides in Streptozotocin-Induced Type 2 Diabetic Mice and Potential Mechanism via PI3K-Akt Signal Pathway. Biomed. Pharmacother. 2017;95:1669–1677. doi: 10.1016/j.biopha.2017.09.104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2017.09.104</ArticleId>
            <ArticleId IdType="pubmed">28954386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wisessaowapak C., Watcharasit P., Satayavivad J. Arsenic Disrupts Neuronal Insulin Signaling through Increasing Free PI3K-P85 and Decreasing PI3K Activity. Toxicol. Lett. 2021;349:40–50. doi: 10.1016/j.toxlet.2021.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.toxlet.2021.06.002</ArticleId>
            <ArticleId IdType="pubmed">34118311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaribeygi H., Farrokhi F.R., Butler A.E., Sahebkar A. Insulin Resistance: Review of the Underlying Molecular Mechanisms. J. Cell. Physiol. 2019;234:8152–8161. doi: 10.1002/jcp.27603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.27603</ArticleId>
            <ArticleId IdType="pubmed">30317615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay G.K., Joseph G.Y., Ofrecio J., Olefsky J.M. Increased P85/55/50 Expression and Decreased Phosphotidylinositol 3-Kinase Activity in Insulin-Resistant Human Skeletal Muscle. Diabetes. 2005;54:2351–2359. doi: 10.2337/diabetes.54.8.2351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.54.8.2351</ArticleId>
            <ArticleId IdType="pubmed">16046301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geering B., Cutillas P.R., Vanhaesebroeck B. Regulation of Class IA PI3Ks: Is There a Role for Monomeric PI3K Subunits? Biochem. Soc. Trans. 2007;35:199–203. doi: 10.1042/BST0350199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BST0350199</ArticleId>
            <ArticleId IdType="pubmed">17371237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goncalves M.D., Hopkins B.D., Cantley L.C. Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N. Engl. J. Med. 2018;379:2052–2062. doi: 10.1056/NEJMra1704560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1704560</ArticleId>
            <ArticleId IdType="pubmed">30462943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hale P.J., López-Yunez A.M., Chen J.Y. Genome-Wide Meta-Analysis of Genetic Susceptible Genes for Type 2 Diabetes. BMC Syst. Biol. 2012;6:1–10. doi: 10.1186/1752-0509-6-S3-S16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1752-0509-6-S3-S16</ArticleId>
            <ArticleId IdType="pmc">PMC3524015</ArticleId>
            <ArticleId IdType="pubmed">23281828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapeller R., Cantley L.C. Phosphatidylinositol 3-kinase. Bioessays. 1994;16:565–576. doi: 10.1002/bies.950160810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bies.950160810</ArticleId>
            <ArticleId IdType="pubmed">8086005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y., Moten A., Lin H.-K. Akt: A New Activation Mechanism. Cell Res. 2014;24:785. doi: 10.1038/cr.2014.57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cr.2014.57</ArticleId>
            <ArticleId IdType="pmc">PMC4085759</ArticleId>
            <ArticleId IdType="pubmed">24797432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iida M., Harari P., Wheeler D., Toulany M. Targeting AKT/PKB to Improve Treatment Outcomes for Solid Tumors. Mutat. Res./Fundam. Mol. Mech. Mutagenesis. 2020;819:111690. doi: 10.1016/j.mrfmmm.2020.111690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mrfmmm.2020.111690</ArticleId>
            <ArticleId IdType="pmc">PMC7169978</ArticleId>
            <ArticleId IdType="pubmed">32120136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mackenzie R.W.A., Elliott B.T. Akt/PKB Activation and Insulin Signaling: A Novel Insulin Signaling Pathway in the Treatment of Type 2 Diabetes. Diabetes Metab. Syndr. Obes. Targets Ther. 2014;7:55. doi: 10.2147/DMSO.S48260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DMSO.S48260</ArticleId>
            <ArticleId IdType="pmc">PMC3928478</ArticleId>
            <ArticleId IdType="pubmed">24611020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning B.D., Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017;169:381–405. doi: 10.1016/j.cell.2017.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.04.001</ArticleId>
            <ArticleId IdType="pmc">PMC5546324</ArticleId>
            <ArticleId IdType="pubmed">28431241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Risso G., Blaustein M., Pozzi B., Mammi P., Srebrow A. Akt/PKB: One Kinase, Many Modifications. Biochem. J. 2015;468:203–214. doi: 10.1042/BJ20150041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20150041</ArticleId>
            <ArticleId IdType="pubmed">25997832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Randall T.A., Gu C., Li X., Wang H., Shears S.B. A Two-Way Switch for Inositol Pyrophosphate Signaling: Evolutionary History and Biological Significance of a Unique, Bifunctional Kinase/Phosphatase. Adv. Biol. Regul. 2020;75:100674. doi: 10.1016/j.jbior.2019.100674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbior.2019.100674</ArticleId>
            <ArticleId IdType="pubmed">31776069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning B.D. Insulin Signaling: Inositol Phosphates Get into the Akt. Cell. 2010;143:861–863. doi: 10.1016/j.cell.2010.11.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.11.040</ArticleId>
            <ArticleId IdType="pmc">PMC3693466</ArticleId>
            <ArticleId IdType="pubmed">21145450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakraborty A. The Inositol Pyrophosphate Pathway in Health and Diseases. Biol. Rev. 2018;93:1203–1227. doi: 10.1111/brv.12392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/brv.12392</ArticleId>
            <ArticleId IdType="pmc">PMC6383672</ArticleId>
            <ArticleId IdType="pubmed">29282838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu Q., Ghoshal S., Rodrigues A., Gao S., Asterian A., Kamenecka T.M., Barrow J.C., Chakraborty A. Adipocyte-Specific Deletion of Ip6k1 Reduces Diet-Induced Obesity by Enhancing AMPK-Mediated Thermogenesis. J. Clin. Investig. 2016;126:4273–4288. doi: 10.1172/JCI85510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI85510</ArticleId>
            <ArticleId IdType="pmc">PMC5096898</ArticleId>
            <ArticleId IdType="pubmed">27701146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bizzarri M., Dinicola S., Cucina A. Modulation of Both Insulin Resistance and Cancer Growth by Inositol. Curr. Pharm. Des. 2017;23:5200–5210. doi: 10.2174/1381612823666170830123634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612823666170830123634</ArticleId>
            <ArticleId IdType="pubmed">28875849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X., Liu G., Guo J., Su Z. The PI3K/AKT Pathway in Obesity and Type 2 Diabetes. Int. J. Biol. Sci. 2018;14:1483. doi: 10.7150/ijbs.27173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.27173</ArticleId>
            <ArticleId IdType="pmc">PMC6158718</ArticleId>
            <ArticleId IdType="pubmed">30263000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kampmann U., Christensen B., Nielsen T.S., Pedersen S.B., Ørskov L., Lund S., Møller N., Jessen N. GLUT4 and UBC9 Protein Expression Is Reduced in Muscle from Type 2 Diabetic Patients with Severe Insulin Resistance. PLoS ONE. 2011;6:e27854.  doi: 10.1371/journal.pone.0027854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0027854</ArticleId>
            <ArticleId IdType="pmc">PMC3218059</ArticleId>
            <ArticleId IdType="pubmed">22114711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saha S. Association between the Membrane Transporter Proteins and Type 2 Diabetes Mellitus. Expert Rev. Clin. Pharmacol. 2020;13:287–297. doi: 10.1080/17512433.2020.1729125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17512433.2020.1729125</ArticleId>
            <ArticleId IdType="pubmed">32066279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaldin-Fincati J.R., Pavarotti M., Frendo-Cumbo S., Bilan P.J., Klip A. Update on GLUT4 Vesicle Traffic: A Cornerstone of Insulin Action. Trends Endocrinol. Metab. 2017;28:597–611. doi: 10.1016/j.tem.2017.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tem.2017.05.002</ArticleId>
            <ArticleId IdType="pubmed">28602209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klip A., McGraw T.E., James D.E. Thirty Sweet Years of GLUT4. J. Biol. Chem. 2019;294:11369–11381. doi: 10.1074/jbc.REV119.008351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.REV119.008351</ArticleId>
            <ArticleId IdType="pmc">PMC6663870</ArticleId>
            <ArticleId IdType="pubmed">31175156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gannon N.P., Conn C.A., Vaughan R.A. Dietary Stimulators of GLUT4 Expression and Translocation in Skeletal Muscle: A Mini-review. Mol. Nutr. Food Res. 2015;59:48–64. doi: 10.1002/mnfr.201400414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mnfr.201400414</ArticleId>
            <ArticleId IdType="pubmed">25215442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaster M., Staehr P., Beck-Nielsen H., Schrøder H.D., Handberg A. GLUT4 Is Reduced in Slow Muscle Fibers of Type 2 Diabetic Patients: Is Insulin Resistance in Type 2 Diabetes a Slow, Type 1 Fiber Disease? Diabetes. 2001;50:1324–1329. doi: 10.2337/diabetes.50.6.1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.50.6.1324</ArticleId>
            <ArticleId IdType="pubmed">11375332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katz E.B., Burcelin R., Tsao T.S., Stenbit A.E., Charron M.J. The Metabolic Consequences of Altered Glucose Transporter Expression in Transgenic Mice. J. Mol. Med. 1996;74:639–652. doi: 10.1007/s001090050068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s001090050068</ArticleId>
            <ArticleId IdType="pubmed">8956150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mora S., Yang C., Ryder J.W., Boeglin D., Pessin J.E. The MEF2A and MEF2D Isoforms Are Differentially Regulated in Muscle and Adipose Tissue during States of Insulin Deficiency. Endocrinology. 2001;142:1999–2004. doi: 10.1210/endo.142.5.8160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/endo.142.5.8160</ArticleId>
            <ArticleId IdType="pubmed">11316766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmes B.F., Sparling D.P., Olson A.L., Winder W.W., Dohm G.L. Regulation of Muscle GLUT4 Enhancer Factor and Myocyte Enhancer Factor 2 by AMP-Activated Protein Kinase. Am. J. Physiol.-Endocrinol. Metab. 2005;289:E1071–E1076. doi: 10.1152/ajpendo.00606.2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00606.2004</ArticleId>
            <ArticleId IdType="pubmed">16105857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koh J.-H., Hancock C.R., Han D.-H., Holloszy J.O., Nair K.S., Dasari S. AMPK and PPARβ Positive Feedback Loop Regulates Endurance Exercise Training-Mediated GLUT4 Expression in Skeletal Muscle. Am. J. Physiol.-Endocrinol. Metab. 2019;316:E931–E939. doi: 10.1152/ajpendo.00460.2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00460.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6580175</ArticleId>
            <ArticleId IdType="pubmed">30888859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S., Czech M.P. The GLUT4 Glucose Transporter. Cell Metab. 2007;5:237–252. doi: 10.1016/j.cmet.2007.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2007.03.006</ArticleId>
            <ArticleId IdType="pubmed">17403369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y., Zhang M., Wang J., Gao T. Nur77 Increases Glucose Transport in Mouse Skeletal Muscle Cells by Activating P38MAPK Under Lipotoxicity. J. Biomater. Tissue Eng. 2020;10:1832–1836. doi: 10.1166/jbt.2020.2521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1166/jbt.2020.2521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkinson B.J., Griesel B.A., King C.D., Josey M.A., Olson A.L. Moderate GLUT4 Overexpression Improves Insulin Sensitivity and Fasting Triglyceridemia in High-Fat Diet–Fed Transgenic Mice. Diabetes. 2013;62:2249–2258. doi: 10.2337/db12-1146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db12-1146</ArticleId>
            <ArticleId IdType="pmc">PMC3712063</ArticleId>
            <ArticleId IdType="pubmed">23474483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J., Herbert T.P. The Role of Mammalian Target of Rapamycin (MTOR) in the Regulation of Pancreatic β-Cell Mass: Implications in the Development of Type-2 Diabetes. Cell. Mol. Life Sci. 2012;69:1289–1304. doi: 10.1007/s00018-011-0874-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-011-0874-4</ArticleId>
            <ArticleId IdType="pubmed">22068611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M., Sabatini D.M. MTOR Signaling at a Glance. J. Cell Sci. 2009;122:3589–3594. doi: 10.1242/jcs.051011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.051011</ArticleId>
            <ArticleId IdType="pmc">PMC2758797</ArticleId>
            <ArticleId IdType="pubmed">19812304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang H., Nie J., Van Skike C.E., Valentine J.M., Orr M.E. Mammalian Target of Rapamycin at the Crossroad between Alzheimer’s Disease and Diabetes. Diabetes Mellit. 2019;1128:185–225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31062331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon M.-S. MTOR as a Key Regulator in Maintaining Skeletal Muscle Mass. Front. Physiol. 2017;8:788. doi: 10.3389/fphys.2017.00788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphys.2017.00788</ArticleId>
            <ArticleId IdType="pmc">PMC5650960</ArticleId>
            <ArticleId IdType="pubmed">29089899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplante M., Sabatini D.M. MTOR Signaling in Growth Control and Disease. Cell. 2012;149:274–293. doi: 10.1016/j.cell.2012.03.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.03.017</ArticleId>
            <ArticleId IdType="pmc">PMC3331679</ArticleId>
            <ArticleId IdType="pubmed">22500797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxton R.A., Sabatini D.M. MTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168:960–976. doi: 10.1016/j.cell.2017.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.02.004</ArticleId>
            <ArticleId IdType="pmc">PMC5394987</ArticleId>
            <ArticleId IdType="pubmed">28283069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J. Absence of S6K1 Protects against Age-and Diet-Induced Obesity While Enhancing Insulin Sensitivity. Nature. 2004;431:200. doi: 10.1038/nature02866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature02866</ArticleId>
            <ArticleId IdType="pubmed">15306821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P., Gan W., Inuzuka H., Lazorchak A.S., Gao D., Arojo O., Liu D., Wan L., Zhai B., Yu Y. Sin1 Phosphorylation Impairs MTORC2 Complex Integrity and Inhibits Downstream Akt Signalling to Suppress Tumorigenesis. Nat. Cell Biol. 2013;15:1340–1350. doi: 10.1038/ncb2860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2860</ArticleId>
            <ArticleId IdType="pmc">PMC3827117</ArticleId>
            <ArticleId IdType="pubmed">24161930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.J., DeStefano M.A., Oh W.J., Wu C., Vega-Cotto N.M., Finlan M., Liu D., Su B., Jacinto E. MTOR Complex 2 Regulates Proper Turnover of Insulin Receptor Substrate-1 via the Ubiquitin Ligase Subunit Fbw8. Mol. Cell. 2012;48:875–887. doi: 10.1016/j.molcel.2012.09.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2012.09.029</ArticleId>
            <ArticleId IdType="pmc">PMC3534931</ArticleId>
            <ArticleId IdType="pubmed">23142081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia D., Shaw R.J. AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. Mol. Cell. 2017;66:789–800. doi: 10.1016/j.molcel.2017.05.032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2017.05.032</ArticleId>
            <ArticleId IdType="pmc">PMC5553560</ArticleId>
            <ArticleId IdType="pubmed">28622524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruderman N.B., Carling D., Prentki M., Cacicedo J.M. AMPK, Insulin Resistance, and the Metabolic Syndrome. J. Clin. Investig. 2013;123:2764–2772. doi: 10.1172/JCI67227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI67227</ArticleId>
            <ArticleId IdType="pmc">PMC3696539</ArticleId>
            <ArticleId IdType="pubmed">23863634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day E.A., Ford R.J., Steinberg G.R. AMPK as a Therapeutic Target for Treating Metabolic Diseases. Trends Endocrinol. Metab. 2017;28:545–560. doi: 10.1016/j.tem.2017.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tem.2017.05.004</ArticleId>
            <ArticleId IdType="pubmed">28647324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim C.T., Kola B., Korbonits M. AMPK as a Mediator of Hormonal Signalling. J. Mol. Endocrinol. 2010;44:87. doi: 10.1677/JME-09-0063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/JME-09-0063</ArticleId>
            <ArticleId IdType="pubmed">19625456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGee S.L., Van Denderen B.J.W., Howlett K.F., Mollica J., Schertzer J.D., Kemp B.E., Hargreaves M. AMP-Activated Protein Kinase Regulates GLUT4 Transcription by Phosphorylating Histone Deacetylase 5. Diabetes. 2008;57:860–867. doi: 10.2337/db07-0843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db07-0843</ArticleId>
            <ArticleId IdType="pubmed">18184930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruderman N.B., Julia Xu X., Nelson L., Cacicedo J.M., Saha A.K., Lan F., Ido Y. AMPK and SIRT1: A Long-Standing Partnership? Am. J. Physiol.-Endocrinol. Metab. 2010;298:E751–E760. doi: 10.1152/ajpendo.00745.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00745.2009</ArticleId>
            <ArticleId IdType="pmc">PMC2853213</ArticleId>
            <ArticleId IdType="pubmed">20103737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu C., Yang R., Sheu M., Chan D., Yang T., Tsai K., Chiang C., Liu S. Advanced Glycation End-products Induce Skeletal Muscle Atrophy and Dysfunction in Diabetic Mice via a RAGE-mediated, AMPK-down-regulated, Akt Pathway. J. Pathol. 2016;238:470–482. doi: 10.1002/path.4674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.4674</ArticleId>
            <ArticleId IdType="pubmed">26586640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X.J., Gauthier M.-S., Hess D.T., Apovian C.M., Cacicedo J.M., Gokce N., Farb M., Valentine R.J., Ruderman N.B. Insulin Sensitive and Resistant Obesity in Humans: AMPK Activity, Oxidative Stress, and Depot-Specific Changes in Gene Expression in Adipose Tissue. J. Lipid Res. 2012;53:792–801. doi: 10.1194/jlr.P022905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1194/jlr.P022905</ArticleId>
            <ArticleId IdType="pmc">PMC3307656</ArticleId>
            <ArticleId IdType="pubmed">22323564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saha A.K., Xu X.J., Lawson E., Deoliveira R., Brandon A.E., Kraegen E.W., Ruderman N.B. Downregulation of AMPK Accompanies Leucine-and Glucose-Induced Increases in Protein Synthesis and Insulin Resistance in Rat Skeletal Muscle. Diabetes. 2010;59:2426–2434. doi: 10.2337/db09-1870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db09-1870</ArticleId>
            <ArticleId IdType="pmc">PMC3279521</ArticleId>
            <ArticleId IdType="pubmed">20682696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruderman N., Prentki M. AMP Kinase and Malonyl-CoA: Targets for Therapy of the Metabolic Syndrome. Nat. Rev. Drug Discov. 2004;3:340–351. doi: 10.1038/nrd1344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd1344</ArticleId>
            <ArticleId IdType="pubmed">15060529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzig S., Shaw R.J. AMPK: Guardian of Metabolism and Mitochondrial Homeostasis. Nat. Rev. Mol. Cell Biol. 2018;19:121–135. doi: 10.1038/nrm.2017.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm.2017.95</ArticleId>
            <ArticleId IdType="pmc">PMC5780224</ArticleId>
            <ArticleId IdType="pubmed">28974774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coughlan K.A., Valentine R.J., Ruderman N.B., Saha A.K. AMPK Activation: A Therapeutic Target for Type 2 Diabetes? DiabetesMetab. Syndr. Obes. Targets Ther. 2014;7:241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4075959</ArticleId>
            <ArticleId IdType="pubmed">25018645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh R., Barden A., Mori T., Beilin L. Advanced Glycation End-Products: A Review. Diabetologia. 2001;44:129–146. doi: 10.1007/s001250051591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s001250051591</ArticleId>
            <ArticleId IdType="pubmed">11270668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unoki H., Yamagishi S. Advanced Glycation End Products and Insulin Resistance. Curr. Pharm. Des. 2008;14:987–989. doi: 10.2174/138161208784139747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161208784139747</ArticleId>
            <ArticleId IdType="pubmed">18473850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowotny K., Jung T., Höhn A., Weber D., Grune T. Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus. Biomolecules. 2015;5:194–222. doi: 10.3390/biom5010194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom5010194</ArticleId>
            <ArticleId IdType="pmc">PMC4384119</ArticleId>
            <ArticleId IdType="pubmed">25786107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uribarri J., Cai W., Ramdas M., Goodman S., Pyzik R., Chen X., Zhu L., Striker G.E., Vlassara H. Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes: Potential Role of AGER1 and SIRT1. Diabetes Care. 2011;34:1610–1616. doi: 10.2337/dc11-0091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc11-0091</ArticleId>
            <ArticleId IdType="pmc">PMC3120204</ArticleId>
            <ArticleId IdType="pubmed">21709297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riuzzi F., Sorci G., Sagheddu R., Chiappalupi S., Salvadori L., Donato R. RAGE in the Pathophysiology of Skeletal Muscle. J. CachexiaSarcopenia Muscle. 2018;9:1213–1234. doi: 10.1002/jcsm.12350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcsm.12350</ArticleId>
            <ArticleId IdType="pmc">PMC6351676</ArticleId>
            <ArticleId IdType="pubmed">30334619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C Tobon-Velasco J., Cuevas E., A Torres-Ramos M. Receptor for AGEs (RAGE) as Mediator of NF-KB Pathway Activation in Neuroinflammation and Oxidative Stress. CNS Neurol. Disord.-Drug Targets. 2014;13:1615–1626. doi: 10.2174/1871527313666140806144831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1871527313666140806144831</ArticleId>
            <ArticleId IdType="pubmed">25106630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greene M.W., Ruhoff M.S., Burrington C.M., Garofalo R.S., Oreña S.J. TNFα Activation of PKCδ, Mediated by NFκB and ER Stress, Cross-Talks with the Insulin Signaling Cascade. Cell. Signal. 2010;22:274–284. doi: 10.1016/j.cellsig.2009.09.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2009.09.029</ArticleId>
            <ArticleId IdType="pubmed">19782747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts A.C., Porter K.E. Cellular and Molecular Mechanisms of Endothelial Dysfunction in Diabetes. Diabetes Vasc. Dis. Res. 2013;10:472–482. doi: 10.1177/1479164113500680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1479164113500680</ArticleId>
            <ArticleId IdType="pubmed">24002671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinto-Junior D.C., Silva K.S., Michalani M.L., Yonamine C.Y., Esteves J.V., Fabre N.T., Thieme K., Catanozi S., Okamoto M.M., Seraphim P.M. Advanced Glycation End Products-Induced Insulin Resistance Involves Repression of Skeletal Muscle GLUT4 Expression. Sci. Rep. 2018;8:8109. doi: 10.1038/s41598-018-26482-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-26482-6</ArticleId>
            <ArticleId IdType="pmc">PMC5970140</ArticleId>
            <ArticleId IdType="pubmed">29802324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morino K., Petersen K.F., Shulman G.I. Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links with Mitochondrial Dysfunction. Diabetes. 2006;55(Suppl. S2):S9–S15. doi: 10.2337/db06-S002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db06-S002</ArticleId>
            <ArticleId IdType="pmc">PMC2995546</ArticleId>
            <ArticleId IdType="pubmed">17130651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brons C., Grunnet L.G. Skeletal Muscle Lipotoxicity in Insulin Resistance and Type 2 Diabetes: A Causal Mechanism or an Innocent Bystander. Eur. J. Endocrinol. 2017;176:R67–R78. doi: 10.1530/EJE-16-0488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-16-0488</ArticleId>
            <ArticleId IdType="pubmed">27913612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reali F., Morine M.J., Kahramanoğulları O., Raichur S., Schneider H.-C., Crowther D., Priami C. Mechanistic Interplay between Ceramide and Insulin Resistance. Sci. Rep. 2017;7:1–9. doi: 10.1038/srep41231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep41231</ArticleId>
            <ArticleId IdType="pmc">PMC5253739</ArticleId>
            <ArticleId IdType="pubmed">28112248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoeks J., Mensink M., Hesselink M.K., Ekroos K., Schrauwen P. Long-and Medium-Chain Fatty Acids Induce Insulin Resistance to a Similar Extent in Humans despite Marked Differences in Muscle Fat Accumulation. J. Clin. Endocrinol. Metab. 2012;97:208–216. doi: 10.1210/jc.2011-1884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2011-1884</ArticleId>
            <ArticleId IdType="pubmed">22031508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaurasia B., Summers S.A. Ceramides in Metabolism: Key Lipotoxic Players. Annu. Rev. Physiol. 2020;83:303–330. doi: 10.1146/annurev-physiol-031620-093815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-physiol-031620-093815</ArticleId>
            <ArticleId IdType="pmc">PMC7905841</ArticleId>
            <ArticleId IdType="pubmed">33158378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandet C.L., Mahfouz R., Véret J., Sotiropoulos A., Poirier M., Giussani P., Campana M., Philippe E., Blachnio-Zabielska A., Ballaire R. Ceramide Transporter CERT Is Involved in Muscle Insulin Signaling Defects under Lipotoxic Conditions. Diabetes. 2018;67:1258–1271. doi: 10.2337/db17-0901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db17-0901</ArticleId>
            <ArticleId IdType="pubmed">29759974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaurasia B., Tippetts T.S., Monibas R.M., Liu J., Li Y., Wang L., Wilkerson J.L., Sweeney C.R., Pereira R.F., Sumida D.H. Targeting a Ceramide Double Bond Improves Insulin Resistance and Hepatic Steatosis. Science. 2019;365:386–392. doi: 10.1126/science.aav3722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aav3722</ArticleId>
            <ArticleId IdType="pmc">PMC6787918</ArticleId>
            <ArticleId IdType="pubmed">31273070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Summers S.A. Ceramides in Insulin Resistance and Lipotoxicity. Prog. Lipid Res. 2006;45:42–72. doi: 10.1016/j.plipres.2005.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.plipres.2005.11.002</ArticleId>
            <ArticleId IdType="pubmed">16445986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neeland I.J., Singh S., McGuire D.K., Vega G.L., Roddy T., Reilly D.F., Castro-Perez J., Kozlitina J., Scherer P.E. Relation of Plasma Ceramides to Visceral Adiposity, Insulin Resistance and the Development of Type 2 Diabetes Mellitus: The Dallas Heart Study. Diabetologia. 2018;61:2570–2579. doi: 10.1007/s00125-018-4720-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-018-4720-1</ArticleId>
            <ArticleId IdType="pmc">PMC6219923</ArticleId>
            <ArticleId IdType="pubmed">30159588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haus J.M., Kashyap S.R., Kasumov T., Zhang R., Kelly K.R., DeFronzo R.A., Kirwan J.P. Plasma Ceramides Are Elevated in Obese Subjects with Type 2 Diabetes and Correlate with the Severity of Insulin Resistance. Diabetes. 2009;58:337–343. doi: 10.2337/db08-1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db08-1228</ArticleId>
            <ArticleId IdType="pmc">PMC2628606</ArticleId>
            <ArticleId IdType="pubmed">19008343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turpin-Nolan S.M., Hammerschmidt P., Chen W., Jais A., Timper K., Awazawa M., Brodesser S., Brüning J.C. CerS1-Derived C18: 0 Ceramide in Skeletal Muscle Promotes Obesity-Induced Insulin Resistance. Cell Rep. 2019;26:1–10. doi: 10.1016/j.celrep.2018.12.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.12.031</ArticleId>
            <ArticleId IdType="pubmed">30605666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S., Huang S., Wang X., Zhang Q., Liu J., Leng Y. Downregulation of Lipin-1 Induces Insulin Resistance by Increasing Intracellular Ceramide Accumulation in C2C12 Myotubes. Int. J. Biol. Sci. 2017;13:1. doi: 10.7150/ijbs.17149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.17149</ArticleId>
            <ArticleId IdType="pmc">PMC5264256</ArticleId>
            <ArticleId IdType="pubmed">28123341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luukkonen P.K., Zhou Y., Sädevirta S., Leivonen M., Arola J., Orešič M., Hyötyläinen T., Yki-Järvinen H. Hepatic Ceramides Dissociate Steatosis and Insulin Resistance in Patients with Non-Alcoholic Fatty Liver Disease. J. Hepatol. 2016;64:1167–1175. doi: 10.1016/j.jhep.2016.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2016.01.002</ArticleId>
            <ArticleId IdType="pubmed">26780287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolak M., Westerbacka J., Velagapudi V.R., Wågsäter D., Yetukuri L., Makkonen J., Rissanen A., Häkkinen A.-M., Lindell M., Bergholm R. Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects with High Liver Fat Content Independent of Obesity. Diabetes. 2007;56:1960–1968. doi: 10.2337/db07-0111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db07-0111</ArticleId>
            <ArticleId IdType="pubmed">17620421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coen P., Hames K., Leachman E., DeLany J., Ritov V., Menshikova E., Dube J., Stefanovic-Racic M., Toledo F., Goodpaster B. Reduced Skeletal Muscle Oxidative Capacity and Elevated Ceramide but Not Diacylglycerol Content in Severe Obesity. Obesity. 2013;21:2362–2371. doi: 10.1002/oby.20381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/oby.20381</ArticleId>
            <ArticleId IdType="pmc">PMC4136513</ArticleId>
            <ArticleId IdType="pubmed">23512750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coope A., Torsoni A.S., Velloso L.A. Mechanisms in Endocrinology: Metabolic and Inflammatory Pathways on the Pathogenesis of Type 2 Diabetes. Eur. J. Endocrinol. 2016;174:R175–R187. doi: 10.1530/EJE-15-1065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-15-1065</ArticleId>
            <ArticleId IdType="pubmed">26646937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hotamisligil G.S. Inflammation, Metaflammation and Immunometabolic Disorders. Nature. 2017;542:177–185. doi: 10.1038/nature21363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature21363</ArticleId>
            <ArticleId IdType="pubmed">28179656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ertunc M.E., Hotamisligil G.S. Lipid Signaling and Lipotoxicity in Metaflammation: Indications for Metabolic Disease Pathogenesis and Treatment. J. Lipid Res. 2016;57:2099–2114. doi: 10.1194/jlr.R066514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1194/jlr.R066514</ArticleId>
            <ArticleId IdType="pmc">PMC5321214</ArticleId>
            <ArticleId IdType="pubmed">27330055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Liu X., Yang Y., He J., Gu H., Jiang M., Huang Y., Liu X., Liu L. Resveratrol Inhibits the Development of Obesity-Related Osteoarthritis via the TLR4 and PI3K/Akt Signaling Pathways. Connect. Tissue Res. 2019;60:571–582. doi: 10.1080/03008207.2019.1601187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03008207.2019.1601187</ArticleId>
            <ArticleId IdType="pubmed">30922122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szabo G., Billiar T.R., Machida K., Crispe I.N., Seki E. Toll-like Receptor Signaling in Liver Diseases. Gastroenterol. Res. Pract. 2010 doi: 10.1155/2010/971270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2010/971270</ArticleId>
            <ArticleId IdType="pmc">PMC3123973</ArticleId>
            <ArticleId IdType="pubmed">21789039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benomar Y., Taouis M. Molecular Mechanisms Underlying Obesity-Induced Hypothalamic Inflammation and Insulin Resistance: Pivotal Role of Resistin/TLR4 Pathways. Front. Endocrinol. 2019;10:140. doi: 10.3389/fendo.2019.00140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2019.00140</ArticleId>
            <ArticleId IdType="pmc">PMC6418006</ArticleId>
            <ArticleId IdType="pubmed">30906281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holland W.L., Bikman B.T., Wang L.-P., Yuguang G., Sargent K.M., Bulchand S., Knotts T.A., Shui G., Clegg D.J., Wenk M.R. Lipid-Induced Insulin Resistance Mediated by the Proinflammatory Receptor TLR4 Requires Saturated Fatty Acid–Induced Ceramide Biosynthesis in Mice. J. Clin. Investig. 2011;121:1858–1870. doi: 10.1172/JCI43378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI43378</ArticleId>
            <ArticleId IdType="pmc">PMC3083776</ArticleId>
            <ArticleId IdType="pubmed">21490391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirosumi J., Tuncman G., Chang L., Görgün C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A Central Role for JNK in Obesity and Insulin Resistance. Nature. 2002;420:333–336. doi: 10.1038/nature01137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature01137</ArticleId>
            <ArticleId IdType="pubmed">12447443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becattini B., Zani F., Breasson L., Sardi C., Giuseppe D’Agostino V., Choo M., Provenzani A., Mo Park J., Solinas G. JNK1 Ablation in Mice Confers Long-term Metabolic Protection from Diet-induced Obesity at the Cost of Moderate Skin Oxidative Damage. FASEB J. 2016;30:3124–3132. doi: 10.1096/fj.201600393R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.201600393R</ArticleId>
            <ArticleId IdType="pmc">PMC6191003</ArticleId>
            <ArticleId IdType="pubmed">27230858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solinas G., Becattini B. JNK at the Crossroad of Obesity, Insulin Resistance, and Cell Stress Response. Mol. Metab. 2017;6:174–184. doi: 10.1016/j.molmet.2016.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmet.2016.12.001</ArticleId>
            <ArticleId IdType="pmc">PMC5279903</ArticleId>
            <ArticleId IdType="pubmed">28180059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.-W., Long J.M., Wynshaw-Boris A., Poli G., Olefsky J., Karin M. IKK-β Links Inflammation to Obesity-Induced Insulin Resistance. Nat. Med. 2005;11:191. doi: 10.1038/nm1185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1185</ArticleId>
            <ArticleId IdType="pubmed">15685170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hotamisligil G.S. Inflammation and Endoplasmic Reticulum Stress in Obesity and Diabetes. Int. J. Obes. 2008;32:S52–S54. doi: 10.1038/ijo.2008.238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ijo.2008.238</ArticleId>
            <ArticleId IdType="pmc">PMC2885768</ArticleId>
            <ArticleId IdType="pubmed">19136991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans J.L., Maddux B.A., Goldfine I.D. The Molecular Basis for Oxidative Stress-Induced Insulin Resistance. Antioxid. Redox Signal. 2005;7:1040–1052. doi: 10.1089/ars.2005.7.1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2005.7.1040</ArticleId>
            <ArticleId IdType="pubmed">15998259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burgos-Morón E., Abad-Jiménez Z., Martinez de Maranon A., Iannantuoni F., Escribano-López I., López-Domènech S., Salom C., Jover A., Mora V., Roldan I. Relationship between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. J. Clin. Med. 2019;8:1385.  doi: 10.3390/jcm8091385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8091385</ArticleId>
            <ArticleId IdType="pmc">PMC6780404</ArticleId>
            <ArticleId IdType="pubmed">31487953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurrle S., Hsu W.H. The Etiology of Oxidative Stress in Insulin Resistance. Biomed. J. 2017;40:257–262. doi: 10.1016/j.bj.2017.06.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bj.2017.06.007</ArticleId>
            <ArticleId IdType="pmc">PMC6138814</ArticleId>
            <ArticleId IdType="pubmed">29179880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., Wang Y., Zou X., Shi Y., Liu Q., Huyan T., Su J., Wang Q., Zhang F., Li X. FOXO1 Inhibition Prevents Renal Ischemia—Reperfusion Injury via CAMP-response Element Binding Protein/PPAR-γ Coactivator-1α-mediated Mitochondrial Biogenesis. Br. J. Pharmacol. 2020;177:432–448. doi: 10.1111/bph.14878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.14878</ArticleId>
            <ArticleId IdType="pmc">PMC6989953</ArticleId>
            <ArticleId IdType="pubmed">31655022</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
